Название продукции:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

CAS:17412-23-6
Молекулярная формула:C8H8ClN3
Чистота:95%+
Номер в каталоге:CM330120
Молекулярная масса:181.62

Упаковочная единица Доступно для заказа Цена ($) Количество
CM330120-50mg in stock ȤȤ
CM330120-100mg in stock ƅƏǠ
CM330120-250mg in stock ƅȋǺ
CM330120-1g in stock ǺƏş
CM330120-5g in stock œşş

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:17412-23-6
Молекулярная формула:C8H8ClN3
Точка плавления:-
Smiles-код:CC1=CC(Cl)=NN2C1=NC(C)=C2
Плотность:
Номер в каталоге:CM330120
Молекулярная масса:181.62
Точка кипения:
Номер Mdl:MFCD27946129
Хранение:

Category Infos

Imidazopyridazines
Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.